| 1. |
- Aasa, Ulrika, et al.
(author)
-
Personalens hälsa och arbetsmiljö
- 2009
-
In: Prehospital akutsjukvård. - Stockholm : Liber. - 9789147084487 ; , s. 33-38
-
Book chapter (pop. science, debate, etc.)
|
|
| 2. |
- Borota, Ljubisa, et al.
(author)
-
Dual lumen balloon catheter - An effective substitute for two single lumen catheters in treatment of vascular targets with challenging anatomy
- 2018
-
In: Journal of clinical neuroscience. - : Elsevier BV. - 0967-5868 .- 1532-2653. ; 51, s. 91-99
-
Journal article (peer-reviewed)abstract
- The aim of this study was to describe our experience in the treatment of various pathological conditions of the cranial and spinal blood vessels and hypervascularized lesions using dual lumen balloon catheters. Twenty-five patients were treated with endovascular techniques: two with vasospasm of cerebral blood vessels caused by subarachnoid hemorrhage, one with a hypervascularized metastasis in the vertebral body, two with spinal dural fistula, four with cerebral dural fistula, three with cerebral arteriovenous malformations, and 13 with aneurysms. The dual lumen balloon catheters were used for remodeling of the coil mesh, injection of various liquid embolic agents, particles and nimodipine, for the prevention of reflux and deployment of coils and stents. The diameter of catheterized blood vessels varied from 0.7 mm to 4 mm. Two complications occurred: perforation of an aneurysm in one case and gluing of the tip of balloon catheter by embolic material in another case. All other interventions were uneventful, and therapeutic goals were achieved in all cases except in the case with gluing of the tip of balloon catheter. The balloons effectively prevented reflux regardless of the type of the embolic material and diameter of blood vessel. The results of our study show that dual lumen balloon catheters allow complex interventions in the narrow cerebral and spinal blood vessels where the safe use of two single lumen catheters is either limited or impossible.
|
|
| 3. |
- Bremer, Anders, 1957-
(author)
-
Den mångfacetterade delaktigheten
- 2016. - 2
-
In: Prehospital akutsjukvård. - Stockholm : Liber. - 9789147114740 ; , s. 65-71
-
Book chapter (other academic/artistic)
|
|
| 4. |
- Bågenholm, Viktoria, et al.
(author)
-
Galactomannan catabolism conferred by a polysaccharide utilisation locus of Bacteroides ovatus : enzyme synergy and crystal structure of a β-mannanase
- 2017
-
In: Journal of Biological Chemistry. - 1083-351X. ; 292:1, s. 229-243
-
Journal article (peer-reviewed)abstract
- A recently identified polysaccharide utilization locus (PUL) from Bacteroides ovatus ATCC 8483 is transcriptionally up-regulated during growth on galacto- and glucomannans. It encodes two glycoside hydrolase family 26 (GH26) β-mannanases, BoMan26A and BoMan26B, and a GH36 α-galactosidase, BoGal36A. The PUL also includes two glycan-binding proteins, confirmed by β-mannan affinity electrophoresis. When this PUL was deleted, B. ovatus was no longer able to grow on locust bean galactomannan. BoMan26A primarily formed mannobiose from mannan polysaccharides. BoMan26B had higher activity on galactomannan with a high degree of galactosyl substitution and was shown to be endo-acting generating a more diverse mixture of oligosaccharides, including mannobiose. Of the two β-mannanases, only BoMan26B hydrolyzed galactoglucomannan. A crystal structure of BoMan26A revealed a similar structure to the exo-mannobiohydrolase CjMan26C from Cellvibrio japonicus, with a conserved glycone region (-1 and -2 subsites), including a conserved loop closing the active site beyond subsite -2. Analysis of cellular location by immunolabeling and fluorescence microscopy suggests that BoMan26B is surface-exposed and associated with the outer membrane, although BoMan26A and BoGal36A are likely periplasmic. In light of the cellular location and the biochemical properties of the two characterized β-mannanases, we propose a schemeof sequential action by the glycoside hydrolasesencodedby the β-mannanPULandinvolved in the β-mannanutilization pathway in B. ovatus. The outer membrane-associated BoMan26B initially acts on the polysaccharide galactomannan, producing comparably large oligosaccharide fragments. Galactomanno-oligosaccharides are further processed in the periplasm, degalactosylated by BoGal36A, and subsequently hydrolyzed into mainly mannobiose by the β-mannanase BoMan26A.
|
|
| 5. |
- Carlsson, Gerd, et al.
(author)
-
The child in the Volvo car
- 1988
-
In: Proceedings of Roads and traffic safety on two continents in Gothenburg, Sweden, 9-11 September 1987. - Linköping : Statens väg- och transportforskningsinstitut. ; , s. 214-236
-
Conference paper (other academic/artistic)
|
|
| 6. |
- Elmqvist, Bodil, et al.
(author)
-
Hållbarhetskrav på biodrivmedel
- 2013
-
In: 15 nedslag i klimatforskningen : dåtid, nutid, framtid. - 9789163723384 ; , s. 195-208
-
Book chapter (peer-reviewed)
|
|
| 7. |
- Haghighi, Sara
(author)
-
Investigation of immunological preconditions in MS patients "MS immunopathic trait"
- 2004
-
Doctoral thesis (other academic/artistic)abstract
- We examined 47 MS patients, 47 healthy siblings and 50 healthy unrelated individuals with blood and CSF analysis and found that 19 % (9/47) of healthy siblings of clinically definite multiple sclerosis patients had an intrathecal immunological reaction to ¡Ý 2 CSF-enriched OCB, in contrast to 4% (2/50) of the unrelated healthy controls. We termed this condition ¡°MS immunopathic trait¡±. We challenged whether this subgroup with the MS immunopathic trait was really asymptomatic, using a more stringent method, high-pass resolution perimetry (HRP). With this method, siblings as a group did not differ from the healthy controls. We measured CSF neurofilament light protein (NFL), and glial fibrillary acidic protein (GFAp), in MS patients and their healthy siblings. There was no increase in CSF GFAp and NFL in the healthy siblings of MS patients, nor in the subgroup of the healthy siblings with the MS immunopathic trait. The verification of the MS immunopathic trait was the precondition for the subsequent aims. The next aim was to clarify whether MS immunopathic trait as a phenotype segregates with any particular pattern, and to examine whether there is any candidate gene or genes. We studied two extended families in which MS not only segregates but also approximately 18% of the CSF investigated blood relatives have the MS immunopathic trait, but with no neurological symptoms. Both families fit a genetic model for autosomal dominant inheritance for the MS immunopathic trait. We performed a genome scan using 285 successful markers, to test the hypothesis that a single gene is causing the MS immunopathic trait in these families. Using a parametric method, we identified regions with suggestive linkage at chromosome 6q12 with a LOD-score of 2.4, and suggestive linkage at chromosome 19q13.2 with a LOD-score of 2.2 when family A was analysed alone. In family B, all MS patients, one individual with the MS immunopathic and all blood relatives had the rare HLA type DRB1*0103, which is associated with other autoimmune diseases. However, the suggestive linkage to chromosome 6q21 raises the question whether this suggestive linkage is a protective gene for MS immunopathic trait or a new susceptibility gene for MS disease. A further aim was to examine whether this phenotype had further neurochemical and immunological characteristics, which could be identical or different from MS. In the healthy siblings group, we found significantly increased CSF levels of sulfatide, CSF galactosylceramide (GalCer), TNF-alpha, and CSF IgG antibodies to measles, and serum IgM antibodies to sulfatide and GalCer, as compared to the controls. It was recently shown that GalCer increases and sulfatide reduces the level of the proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha. The occurrence of this differential effect in MS was supported by a significant correlation between CSF GalCer and IL-6 levels in the MS immunopathic trait group. This finding may indicate a greater likelihood for individuals with the higher levels of GalCer to have increased level of IL-6. The absence of axonal damage markers as CSF GFAp and NFL in the healthy siblings, in combination with increased CSF levels of sulfatide, allowed for the tentative conclusion that myelin damage is an earlier event than axonal damage. The present material should give us an opportunity to study whether antiviral or antimyelin antibodies are the earlier event and to further redefine the MS immunopathic trait phenotype.
|
|
| 8. |
|
|
| 9. |
- Herlitz, Johan, et al.
(author)
-
Long-term morbidity in patients where the initial suspicion of myocardial infarction was not-confirmed
- 1988
-
In: Clinical Cardiology. - : John Wiley & Sons, Inc.. - 0160-9289 .- 1932-8737. ; 11:4, s. 209-214
-
Journal article (peer-reviewed)abstract
- The morbidity and mortality during a 5-year follow-up in thcoronary care unit with chest pain presenting an initial suspicion of acute infarction, but in whom the diagnosis could not be confirmed, is reported. They were divided into four groups: Possible myocardial infarction (29%), angina pectoris (24%), chest pain of uncertain origin (32%), and nonischemic cause of chest pain (15%). The overall 5-year mortality rate was 13.3 % and did not differ substantially between the four groups. During the 5-year follow-up a confirmed myocardial infarction developed in 28% and 22% among patients with the diagnosis possible infarction and angina pectoris, respectively, and in about 10% of the remaining patients. Stroke developed in 4% of patients with possible infarction and in 2-3% in the remaining subgroups. In all, 59% of the patients were rehospitalized for a mean duration of 30 days in hospital. Among survivors at 5 years, 54% reported chest pain equivalent to angina pectoris and 25% had chest pain daily. A high prevalence of angina pectoris, a high frequency of rehospitalization due to chest pain, and a high consumption of cardiovascular drugs could be found in all four groups.
|
|
| 10. |
- Hollander, Johan, et al.
(author)
-
Rates of gene flow in a freshwater snail and the evolution of phenotypic plasticity
- 2017
-
In: Biological Journal of the Linnean Society. - : Oxford University Press (OUP). - 0024-4066 .- 1095-8312. ; 121:4, s. 764-770
-
Journal article (peer-reviewed)abstract
- The evolution of phenotypic plasticity requires a number of conditions. Selection of plasticity is favoured when the organism experience environmental change, costs are low and cues are reliable about the environmental heterogeneity. However, organisms living in stable environments, not showing constitutive traits but a large amount of plasticity, are predicted to demonstrate high rates of gene flow in order for selection to favour the evolution of phenotypic plasticity, which accordingly should provide weak genetic structures across populations. We used the pulmonate freshwater gastropod Radix balthica, a species with known and considerable shell shape variation due to predator-induced plasticity, and used amplified fragment length polymorphism markers to test if the rate of gene flow can explain the evolution of phenotypic plasticity. Since R. balthica inhabit water bodies with different but consistent predator regimes, we envisaged a large dispersal rate. However, we found a contradictory result with clear population structures, even among adjacent ponds in southern Sweden. We discuss this apparent paradox in contrast to the evolution of ecotype formation, colonization mechanisms that have the potential to reduce gene flow and, in the context of costs of plasticity, we consider new perspectives about relaxed and variable selection that may drive the evolution of phenotypic plasticity.
|
|
